Literature DB >> 9706516

Gastro-esophageal decongestion and splenectomy GEDS (Hassab), in the management of bleeding varices. Review of literature.

M A Hassab1.   

Abstract

The use of Doppler flowmetry proved the importance of hypervolemia in bleeding and showed that GEDS enhances liver perfusion confirming our findings in the Sixties. Perhiatal devascularization of lower 3-4 inches of the esophagus, complete separation of the stomach from its bed, ligation of the left gastric artery at the lesser curvature, peritonization of greater curvature, nursing the patient on his right side, suction drainage of the splenic bed, and early respiratory exercises are essential technical points. Combination with sclerotherapy is useful but esophageal transection is harmful. Variceal rebleeding varied from 5.5% in 3 years to 7% in 10 years, when done properly, to 17% and 18.8% when done incompletely; higher rates include minor bleeding of gastritis. Encephalopathy varied from nil to minimal incidence of mild forms. Thus when done properly GEDS is as effective in controlling bleeding as DSRS with better liver, better heart, better life and better survival with nil or minimal encephalopathy. Combined with sclerotherapy it forms the ideal therapy for bleeding varices in all types of pathology.

Entities:  

Mesh:

Year:  1998        PMID: 9706516

Source DB:  PubMed          Journal:  Int Surg        ISSN: 0020-8868


  12 in total

1.  Long-term results of esophagogastric devascularization and splenectomy associated with endoscopic treatment in schistosomal portal hypertension.

Authors:  Fabio Ferrari Makdissi; Paulo Herman; Vincenzo Pugliese; Roberto de Cleva; William Abrão Saad; Ivan Cecconello; Luiz Augusto Carneiro D'Albuquerque
Journal:  World J Surg       Date:  2010-11       Impact factor: 3.352

2.  Transabdominal modified devascularization procedure with or without esophageal stapler transection--an operation adequate for effective control of a variceal bleed. Is esophageal stapler transection necessary?

Authors:  M Johnson; S Rajendran; T G Balachandar; D Kannan; S Jeswanth; P Ravichandran; R Surendran
Journal:  World J Surg       Date:  2006-08       Impact factor: 3.352

3.  What are the essential components of a transabdominal devascularization procedure for bleeding esophageal varices?

Authors:  Dinesh Singhal; Neerav Goyal; A S Soin; Subash Gupta; S Nundy
Journal:  World J Surg       Date:  2007-04       Impact factor: 3.352

4.  Current role of surgery in portal hypertension.

Authors:  Sujoy Pal
Journal:  Indian J Surg       Date:  2011-12-13       Impact factor: 0.656

5.  Long-term results of the paraesophagogastric devascularization with or without esophageal transection: which is more suitable for variceal bleeding?

Authors:  He-yun Zhang; Wen-bin Li; Hua Ye; Zhi-yu Xiao; Yao-rong Peng; Jie Wang
Journal:  World J Surg       Date:  2014-08       Impact factor: 3.352

6.  Gastrointestinal complications of schistosomiasis.

Authors:  T W Schafer; B R Hale
Journal:  Curr Gastroenterol Rep       Date:  2001-08

7.  Radiofrequency ablation plus devascularization is the preferred treatment of hepatocellular carcinoma with esophageal varices.

Authors:  Ke Zhang; Li Jiang; Zhe Jia; Yao Zhang; Rong He; Zhenhao Ding; Yi Mu
Journal:  Dig Dis Sci       Date:  2014-11-28       Impact factor: 3.199

8.  New operative method for fundal variceal bleeding: fundectomy with periesophagogastric devascularization.

Authors:  Ho-Seong Han; Nam-Joon Yi; Young-Woo Kim; Gary D Fleischer
Journal:  World J Surg       Date:  2004-03-04       Impact factor: 3.352

9.  Esophagogastroduodenoscopy in a public referral hospital in Lilongwe, Malawi: spectrum of disease and associated risk factors.

Authors:  Lindsey L Wolf; Rahim Ibrahim; Changchun Miao; Arturo Muyco; Mina C Hosseinipour; Carol Shores
Journal:  World J Surg       Date:  2012-05       Impact factor: 3.282

10.  Porto-systemic shunt using adrenal vein as a conduit; an alternative procedure for spleno--renal shunt.

Authors:  Unal Aydin; Pinar Yazici; Murat Kilic
Journal:  BMC Surg       Date:  2007-06-07       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.